JSC „Grindeks” informs that development of medications for the anti-HIV / AIDS therapy group is not on the agenda. The decisions regarding the project “Combination of nucleid reverse transcriptase inhibitors with Mildronate® in anti - HIV / AIDS therapy” will be taken during the further business development. At the moment “Grindeks” research activities are targeted on successful completion of the wide scope research program in cardiology, which is the main therapeutic group of company. Chairman of the Council of “Grindeks” Kirovs Lipmans: „Rigorous business studies regarding Research and Development projects are evaluated every year. According to business strategy, investments in Research and Development are focused on projects that are already nearing completion and with high return.” As informed previously, “Grindeks” engaged in project “Combination of nucleid reverse transcriptase inhibitors with Mildronate® in anti - HIV / AIDS therapy” in 2006. About “Grindeks” “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. “Grindeks” Group consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. JSC “Grindeks” shares are listed in the Official List of “NASDAQ OMX Riga”. You are kindly invited to www.grindeks.lv to get to know more about our company! Further information: Laila Kļaviņa Head of the Communications Department JSC “Grindeks” E-mail: laila.klavina@ grindeks.lv Phones: +371 67083370, +371 29256012